Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Dwarfism, Pituitary 1Diabetes Mellitus, Type 2 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms × somapacitan × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡